Population pharmacokinetic-pharmacodynamic modeling of mycophenolate and tacrolimus in pediatric kidney transplant recipients

Mycophenolic acid (MPA) and tacrolimus (TAC) are approved for use in post-transplant immunosuppressants to prevent graft rejection after solid organ transplantation. MPA and TAC are frequently used in combination as an immunosuppressive regimen in pediatric kidney transplant recipients. However, these two drugs have narrow therapeutic ranges and large interindividual pharmacokinetic and pharmacodynamic variabilities. What’s more, in recent years, some previous studies have reported that there were drug-drug interactions (DDI) between TAC and MPA. Therefore, a new study is needed to build a population pharmacokinetic-pharmacodynamic model for TAC and MPA in pediatric kidney transplant recipients. The overall goal is to establish a population structural model incorporating both drugs and identify clinically significant covariates. Evaluation of the influence of drug-drug interactions and individual variabilities on the PK-PD changes will provide striking improvement in post-transplant immunosuppressive outcomes in pediatric patients treated with TAC and MPA.

Faculty Supervisor:

Tony Kiang

Student:

Partner:

Seoul National University

Discipline:

Life Sciences

Sector:

Education

University:

University of Alberta

Program: